文献速递MDS 与骨髓增殖性肿瘤白血病

放射性碘治疗分化型甲状腺癌患者发生慢性髓系肿瘤的风险

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.
PubMed 文献 · Leukemia · 2017-11-06

研究基于SEER登记1973至2014年148215例分化型甲状腺癌患者,其中46%接受辅助放射性碘治疗,中位随访6.6年,分别有77例和66例发生骨髓增生异常综合征(MDS)和骨髓增殖性肿瘤(MPN)。与背景人群相比,辅助放射性碘治疗后第2至3年MDS和MPN相对风险显著升高,且风险与肿瘤大小≥2 cm或区域病变显著相关;发生MDS者中位总生存更短。

要点

  • 放射性碘治疗后第2至3年MDS相对风险3.85(95%CI 1.7-7.6;P=0.0005),MPN相对风险3.13(95%CI 1.1-6.8;P=0.012)。
  • 放射性碘治疗相关MDS和MPN的过剩绝对风险分别为每10万人年6.6例和8.1例。
  • 发生MDS的分化型甲状腺癌幸存者中位总生存10.3年 vs 22.5年(P<0.001)。

核心结论

  • 分化型甲状腺癌的放射性碘治疗与MDS风险增加相关,潜伏期短且生存较差。

研究设计与样本

  • 从SEER登记库1973至2014年识别148215例分化型甲状腺癌患者,54%接受确定性甲状腺切除术,46%接受辅助放射性碘治疗,中位随访6.6年。

主要发现

  • 77例和66例分化型甲状腺癌患者分别发生MDS和MPN。
  • 与背景人群相比,辅助放射性碘治疗后第2至3年MDS相对风险3.85(95%CI 1.7-7.6;P=0.0005),MPN相对风险3.13(95%CI 1.1-6.8;P=0.012),单纯甲状腺切除术后未见升高。
  • 放射性碘治疗相关MDS和MPN的过剩绝对风险分别为每10万人年6.6例和8.1例。
  • 风险增加与分化型甲状腺癌大小≥2 cm或区域病变显著相关。
  • 发生MDS的分化型甲状腺癌幸存者中位总生存10.3年 vs 22.5年(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Exposure to ionizing radiation increases the risk of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), but such risks are not known in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI). A total of 148 215 WDTC patients were identified from Surveillance, Epidemiology and End Results registries between 1973 and 2014, of whom 54% underwent definitive thyroidectomy and 46% received adjuvant RAI. With a median follow-up of 6.6 years, 77 and 66 WDTC patients developed MDS and MPN, respectively. Excess absolute risks for MDS and MPN from RAI treatment when compared to background rates in the US population were 6.6 and 8.1 cases per 100 000 person-years, respectively. Compared to background population rates, relative risks of developing MDS (3.85 (95% confidence interval, 1.7-7.6); P=0.0005) and MPN (3.13 (1.1-6.8); P=0.012) were significantly elevated in the second and third year following adjuvant RAI therapy, but not after thyroidectomy alone. The increased risk was significantly associated with WDTC size ⩾2 cm or regional disease. Development of MDS was associated with shorter median overall survival in WDTC survivors (10.3 vs 22.5 years; P<0.001). These data suggest that RAI treatment for WDTC is associated with increased risk of MDS with short latency and poor survival.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Molenaar RJ, Pleyer C, Radivoyevitch T, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia. 2017. PMID: 29104287. doi:10.1038/leu.2017.323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。